Galera Therapeutics (GRTX)
OTHER OTC:GRTX
Want to see GRTX full AI Analyst Report?
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$0.02 - $0.15
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$17.43M
Enterprise Value$950.89K
Total Cash (Recent Filing)$6.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta1.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding203,268,890
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Merger & FinancingThe Obsidian all-stock merger plus an oversubscribed $350M private placement materially improves funding visibility through mid-2028, repositions Galera into a larger immuno-oncology platform and funds key program milestones; structurally reduces near-term cash risk and raises program advancement odds.
Balance-sheet DeleveragingA sharp reduction of debt to zero and restoration of positive equity by 2025 represent a meaningful repair of solvency and leverage metrics. This deleveraging lowers bankruptcy and financing premium risk, improving long-term access to capital and strategic optionality for pipeline development and partnerships.
Simplified Capital Structure & GovernanceEliminating the Series B preferred simplifies equity, aligns holders on common stock economics, and reduces structural complexity. Combined with charter updates for written consent and board tools, this creates clearer governance and expedites corporate actions, aiding long-term strategic execution and M&A flexibility.
Bears Say
Pre-revenue Operating LossesGalera remains a pre-revenue biotech with persistent negative EBIT/EBITDA and historically material cash burn. Without durable operating cash flow or commercial revenues, the company depends on external financing and milestone outcomes, which raises long-term execution and viability risk if development fails or financing conditions tighten.
Thin Capital CushionEven after deleveraging, the balance sheet shows a modest asset base and limited equity cushion. Such thin capitalization reduces the firm’s ability to absorb clinical setbacks or fund parallel programs organically, increasing dependency on external capital and making operations sensitive to funding timing and market conditions.
Post-merger Minority Stake & Dilution RiskUnder the merger, legacy Galera shareholders become a small minority (~1.8% pro forma), limiting control and upside capture. Concurrent large private placement and charter changes that expand authorized shares create ongoing dilution risk, reducing long-term returns for current holders absent significant contingent recoveries.
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $17.43M.
When is Galera Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Galera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 203,268,890 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
37.09% Insiders
<0.01% Mutual Funds
1.45% Other Institutional Investors
61.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---